Thera-SAbDab

MARGETUXIMAB

>   Structural Summary
TherapeuticMargetuximab
TargetERBB2
Heavy ChainQVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS
Light ChainDIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedRaven biotechnologies, GC Pharma, Green Cross, MacroGenics, Merck Sharp & Dohme
Conditions ApprovedBreast cancer
Conditions ActiveGastric cancer, Oesophageal cancer
Conditions DiscontinuedBladder cancer, Non-small cell lung cancer, Ovarian cancer, Haematological malignancies, Solid tumours
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy